Navigation Links
Animal models that help translate regenerative therapies from bench to bedside
Date:2/11/2010

New Rochelle, NY, February 11, 2010Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models. The highlights of a recent workshop that explored the need for and current status of animal models for musculoskeletal regenerative medicine are presented in a special issue of Tissue Engineering, Part B: Reviews, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com) The issue is available free online (www.liebertpub.com/ten).

The production of specially engineered tissues to restore the function and viability of cartilage or meniscus in the knee, for example, or of degenerating intervertebral discs in the spine, will likely one day be commonplace. In the meantime, however, there is substantial need for better and standardized animal models for the development and testing of these innovative techniques. At the National Institutes of Health (NIH)-sponsored workshop "Translational Models for Musculoskeletal Tissue Engineering and Regenerative Medicine," leaders in the field described available models, outlined the unmet needs, and discussed the translational pathways for clinical testing and therapeutic use.

Mark Lee, PhD, and colleagues from the U.S. Food and Drug Administration (FDA, Rockville, MD) explained how the complexity of engineered tissue constructs, often containing a combination of cells, scaffolds, and other factors, creates challenges for product characterization and manufacturing. In their paper "Considerations for Tissue-Engineered and Regenerative Medicine Product Development Prior to Clinical Trials in the United States," they provide resources and recommendations to help product developers optimize the safety and effectiveness of engineered tissues ready for testing in clinical trials.

Focusing on the challenges of applying regenerative medicine technologies to the surgical repair of torn rotator cuffs, Kathleen Derwin, PhD, and coworkers from the Cleveland Clinic in Ohio identified appropriate animal models for research, development, and testing of repair strategies. In their paper, "Preclinical Models for Translating Regenerative Medicine Therapies for Rotator Cuff Repair," they emphasize the need for discriminating preclinical models in which researchers can experiment with the materials and procedures that will ultimately be used to treat human patients.

Damage and degeneration of cartilage is a leading cause of pain and disability associated with the development of osteoarthritis. In their review article "Animal Models for Cartilage Regeneration and Repair," Michal Szczodry, MD, Stephen Bruno, and Constance Chu, MD, from the University of Pittsburgh (Pennsylvania), emphasize the value of animal studies to understand the disease process underlying joint degeneration and to develop effective treatments for cartilage injuries.

"The workshop and manuscripts they produced provide an excellent summary of the tools we have available to translate new technologies forward, toward clinical studies. They also identify the critical gaps in our current knowledge," says Anthony Ratcliffe, PhD, President and CEO of Synthasome, Inc., and a guest editor of this special issue.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. Animals cope with climate change at the dinner table
2. New on-off switch triggers and reverses paralysis in animals with a beam of light
3. NIFA awards funding for animal health and production research
4. Better food makes high-latitude animals bigger
5. Oral COTI-2 is effective in a second animal model of human pancreatic cancer
6. Animal behavioral studies can mimic human behavior
7. Roe of marine animals is best natural source of omega-3
8. ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER
9. New on-off switch triggers and reverses paralysis in animals with a beam of light
10. Master regulator found for regenerating nerve fibers in live animals
11. Geologist analyzes earliest shell-covered fossil animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology: